Brief: Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66
13/03/2018 20:07
March 13 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND
REPORTS
FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER
31, 2017
* REMAINS ON TRACK TO FILE EUROPEAN MARKETING AUTHORIZATION
APPLICATIONS FOR BPX-501 AND RIMIDUCID IN 2019
* QTRLY LOSS PER SHARE $0.66
* Q4 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS
I/B/E/S
Source text for Eikon: ID:nGNX4Xw8rt
Further company coverage: BLCM.O
(Reuters.Brief@thomsonreuters.com)
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview